STRIDE: Strength of The Calf Muscles and Their Role In Declining Effectiveness of Movement With Aging

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Leicester

About this trial

The calf muscles (plantarflexors) are the most important muscles for walking, running and daily activities. Weakness of these muscles through aging and disease significantly impact a person's ability to walk and complete daily activities. By assessing calf strength, it is possible to identify people at risk of falls, and a condition called sarcopenia (which means loss of muscle mass, strength and function). Unfortunately, most of the studies that have examined this have used specialist equipment unavailable to hospital staff. Our study aims to use commercially available equipment to explore the relationship between plantarflexor muscle strength and physical performance in adults living with or without sarcopenia, including those at risk of it. The study will determine if stronger/weaker calf muscles associated with sarcopenia influence the ability to walk and do things more easily. We will complete strength tests of the calf, thigh and hand, assess walking using a special camera system, use an ultrasound scan to look at the Achilles tendon, use a scan to look at how stiff your calf muscles are, assess your body composition, complete a physical performance test and some questionnaires. Each participant will complete the measures during one clinic visit

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participant is able and willing to provide informed consent to participate in the study

Aged 18 years or over

Ambulatory status: able to walk independently with or without aids

Able to attend clinic

Disqualifiers

Participant is unwilling or unable to give informed consent.

Palliative/ end of life

Moderate to severe communication difficulties/ cognitive function

Immobile

Trial population

The study population is individuals over the age of 18 years, who may or may not have sarcopenia. Individuals will be determined as either sarcopenic or non-sarcopenic by completing the outcome measures (SARC-F questionnaire, Grip strength, BIA and SPPB) and using the cut-off values as recommended by the European Working Group on Sarcopenia in Older People 2 consensus.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • No intervention (observational study)

    Other intervention

    No intervention (observational study)

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Sarcopenic1 intervention
Group B: Non Sarcopenic1 intervention

Trial outcomes

Primary outcomes

1

Isometric plantarflexor strength testing

Isometric plantarflexor strength will be tested using the Fysiometer C-station

Time frame
Baseline

Secondary outcomes

1

Theia markerless motion capture system

Gait will be assessed using Theia 3D (Theia Markerless Inc., Kingston, ON, Canada). Theia 3D is a commercial markerless motion capture system which uses multiple cameras to capture video footage of physical performance, tracking 124 keypoints producing 3D models. Calibration it completed prior to recording. Data is processed in Theia 3D and analysed in Visual 3D software. Measures such as gait speed and pattern, forces, joint angles, stride length and cadence will be collected.

Time frame
Baseline
2

Ultrasound Tissue Characterization Imaging

Imaging of the Achilles Tendon to identify structural changes to the Achilles tendon.

Time frame
Baseline
3

Elastography

Imaging of the Plantarflexors and Achilles Tendon to understand muscle stiffness and tissue mechanical properties

Time frame
Baseline
4

Grip strength

A Jamar hand dynamometer will be used, measuring grip strength in kilograms

Time frame
Baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Leicester

Lead sponsor

University Hospitals, Leicester

Collaborator

This trial is not recruiting at the moment. You can still explore other options: